目录号：A2025 别名: Cosentyx, AIN457 中文名称：苏金单抗
For research use only.
Not for use in humans.
Secukinumab (anti-IL-17A) (Cosentyx, AIN457) 是人IgG1κ单克隆抗体，与蛋白 interleukin (IL)-17A 结合，可用于治疗牛皮癣、强直性脊柱炎和银屑病关节炎等。MW=147.9 kDa。
|产品描述||Secukinumab (anti-IL-17A) (Cosentyx, AIN457) 是人IgG1κ单克隆抗体，与蛋白 interleukin (IL)-17A 结合，可用于治疗牛皮癣、强直性脊柱炎和银屑病关节炎等。MW=147.9 kDa。|
Healthy donors show both significantly less frequent T cell responses and lower numbers of pre-existing T cells to Secukinumab than other approved therapeutic antibodies used to treat plaque psoriasis.
The validation study using secukinumab shows similar results to the DSS-induced colitis model in Il17a−/− mice. WT mice that received secukinumab tend to lose less weight than those who do not. In the validation study using secukinumab, chronic colitis is induced in all the Rag2−/− mice that received T cells. Although statistical significance is not achieved in the comparison between the T cell transfer with secukinumab group and the group that does not receive secukinumab due to a small sample size, administration of secukinumab can not attenuate chronic colitis.
|配制||PBS buffer, pH 7.2|
|储存条件||Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles|